Fund moves
5.7%Stake · was 5.7%
A Schedule 13G is filed by holders above 5% who say they will not try to influence the company. Index funds and large asset managers file most of them.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Traded Nov 13, 2026 · Filed Nov 16, 2026
Dyne Therapeutics's Head of R&D and CMO sold $44K of Dyne Therapeutics shares. The filing says it was made under a pre-arranged trading plan.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
open market sale
Code S — open-market or private sale
~$43,799
Shares × reported transaction price
8 days after results of Nov 5, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $17.16 on Nov 13, 2026, 20% above its 52-week low and 36% below its high, after a 13% rise over the previous 30 trading days
52-week range $14.25 (Oct 16, 2026) to $26.78 (Aug 19, 2026), 23% of the way up, from 250 adjusted closes. 30 trading days earlier: $15.20 on Oct 2, 2026. Describes the past only, not a forecast
RSI 49, 11% under its 200-day average, 1% above its 50-day average, 36% below the 52-week high, 20-day volatility 62% a year, against the S&P 500: +14 points over 1 month, −30 points over 3 months, −7 points over 6 months
From the adjusted closes up to Nov 13, 2026. RSI: Wilder's 14-day relative strength index (0 to 100). Averages: the last 50 and 200 closes. Volatility: standard deviation of the last 20 daily returns, annualised. S&P 500: the stock's move minus SPY's between the same dates (21, 63 and 126 trading days). Describes the past only, not a forecast
Footnote references a pre-arranged trading plan (Rule 10b5-1)
Only flagged when a footnote says so; never inferred
Fund moves
A Schedule 13G is filed by holders above 5% who say they will not try to influence the company. Index funds and large asset managers file most of them.
Johanna Friedl-naderer (Chief Commercial Officer) sold ~$3.9K of Dyne Therapeutics
Planned saleJohn Cox (CEO & President) sold ~$93K of Dyne Therapeutics
Planned saleEvery dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.